2017 2018 · PARI PRODUCT OVERVIEW 2017 / 2018 BREATHE FREELY. WITH PARI. oduct overview 2017 /...

PARI PRODUCT OVERVIEW 2017 / 2018

www.pari.com

BREATHE FREELY.

WITH PARI.

Product overview

2017 / 2018

GLOSSAR

TOR .................................. Total Output Rate, mg/min Gravimetrically determined total mass output per minute

MMD ............................... Mass Median Diameter, μm Diameter at which 50% of the particles by mass are smaller or equal Mass fractions < 5 μm ... Mass of medication in droplets smaller than 5 micrometres (1 µm= one 100,000th of a metre)

AIRWAYS

Up

per

Air

way

sLo

wer

Air

way

s

Windpipe

Throat

Larynx

Nasalcavities

Nose

Bronchi

HOLDING CHAMBER

VORTEX® 38VORTEX® Tracheo 40

SALINE SOLUTIONS

PARI NaCl Inhalation Solution 42MucoClear® 3% Inhalation Solution 43MucoClear® 6% Inhalation Solution 44

PEP SYSTEMS

PARI PEP Systems 46PARI O-PEP 47

DIAGNOSTICS

SpiroSense®Pro 50mySpiroSense® 51PARI PEAK FLOW METER 52

CLINIC PRODUCTS

PARI CENTRAL 54PARI LC SPRINT® CENTRAL 55VORTEX® 56Nebulisers and Accessories 57 PARI Filter/Valve Set 58

FURTHER INFORMATION

PARI International 60PARI Publication List 62

INHALATION DEVICES

UPPER AIRWAYS PARI SINUS 8 PARI MONTESOL Nasal Douche and Nasal Rinse 9

LOWER AIRWAYS VELOX® and VELOX® Junior 12 PARI BOY® mobile S 13PARI BOY® SX 14PARI JuniorBOY® SX 15PARI TurboBOY® SX 16PARI mini® 17PARI COMPACT 18

SPECIAL THERAPYeFlow®rapid nebuliser system 20

NEBULISERS

Which nebuliser is right? 24PARI LC SPRINT® Family 26PARI PIF Control 27PARI LC PLUS® Nebuliser 28Masks & Mouthpieces for Nebuliser 29PARI Year Packs 31PARI Nebulisers 34

CLI

NIC

PR

OD

UC

TSD

IAG

NO

STIC

SPE

P SY

STEM

SSA

LIN

E SO

LUTI

ON

SH

OLD

ING

C

HA

MB

ERN

EBU

LISE

RS

INH

ALA

TIO

N

DEV

ICES

4

PARI SINUSItem No. 028G1000

• PARI LC SPRINT SINUS Nebuliser• PARI SINUS tube system

PARI LC SPRINT SINUSYear PackItem No. 023G2860

n.a.** • Only device for treatment of the paranasal sinuses: Pulsating aerosol transports the medication directly into the paranasal sinuses

• With PARI LC SPRINT nebuliser also suitable for the lower airways (accessories available)

SinusitisSinubronchitis

8

VELOX® JuniorItem No. 055G1101

Available in selected countries only

• VELOX control unit• VELOX membrane nebuliser• Mouthpiece• VELOXcare• Power adapter• Case• SMARTMASK Baby

VELOX Junior Year PackItem No. 055G3110

• Fast – Inhalation in about 3 min.• Quiet – Almost silent• Mobile – Small and battery-powered• As effective as PARI JuniorBOY SX• Extra-soft baby mask

Bronchial asthma/Allergic asthmaAcute and chronic bronchitisAtelectasis or bronchiectasisCOPD

12

PARI JuniorBOY® SX Item No. 085G3301

• Mouthpiece• BABY mask size 2 / BABY bend• PARI LC SPRINT Junior Nebuliser

PARI JuniorBOY Year Pack SItem No. 023G1111

• Faster inhalation than conventional inhalation systems due to 1.6 bar motor• Clinically tested nebuliser system developed specially for children• Fine droplets for small airways• Inhalation possible while lying down

Bronchial asthma/Allergic asthmaAcute and chronic bronchitisAtelectasis or bronchiectasis

15

VELOX®

Item No. 055G1001

• VELOX control unit• VELOX membrane nebuliser• Mouthpiece• VELOXcare• Power adapter• Case

VELOX Year PackItem No. 055G3010

• Fast – Inhalation in about 3 min.• Quiet – Almost silent• Mobile – Small and battery-powered• As effective as PARI BOY SX


12

PARI BOY® SX Item No. 085G3001

• Mouthpiece• Child mask soft• PARI LC SPRINT Nebuliser• Additional red nozzle attachment• LC Interrupter• PIF Control

PARI BOY SX Year PackItem No. 023G8511

• Faster inhalation than conventional inhalation systems due to 1.6 bar compressor• Extra equipment for severe chronic diseases of the airways• Additional nozzle attachment for days of heavy obstruction and mucus production

Bronchial asthma/Allergic asthmaAcute and chronic bronchitisAtelectasis or bronchiectasisPulmonary emphysemaCOPD

14

PARI TurboBOY® SX Item No. 085G3201

• Mouthpiece• Child mask soft• Adult mask soft• PARI LC SPRINT Nebuliser

PARI TurboBOY Year Pack SItem No. 023G1011

• Basic equipment for acute and chronic diseases of the airways• Faster inhalation than conventional inhalation systems due to 1.6 bar compressor• Highly effective, clinically tested nebuliser system


16

PARI mini® Item No. 047G4001

• Mouthpiece• Child mask soft• PARI LC SPRINT Nebuliser


• Small and light inhalation device• Can be used anywhere in the world with the accompanying multi-voltage power adapter

COPDAllergic asthmaAcute and chronic bronchitis

17

PARI BOY® mobile SItem No. 047G1000

• Moutpiece• Child mask soft• PARI LC SPRINT Nebuliser• 12 V vehicle electrical socket• Convenient shoulder bag


• Portable, battery powered compressor nebuliser provides treatment without relying on mains power• Rechargeable battery can be charged anywhere in the world with the accompanying multi-voltage power adapter or even with the

12 V car socket• Carrying case included in the delivery for practical stowage of the device when you travel


13

PARI COMPACT

Item No. 052G1002

• Mouthpiece• Child mask soft• PARI LC PLUS Nebuliser

– • High PARI quality standard• Clinically tested nebuliser system

Bronchial asthma/Allergic asthmaAcute and chronic bronchitisCOPD

18

eFlow®rapidItem No. 178G1005

• 2 complete nebulisers• Storage bag• Easycare cleaning appartus• Nebuliser bag• Power adapter/batteries

– • Special device for severe diseases of the airways with broad treatment spectrum• Short inhalation times• Silent, discreet operation• Lightweight, small and portable• Display provides feedback during inhalation

Cystic fibrosisPrimary ciliary dyskinesia (PCD)

20

Inhalation DevicesLo

wer

air

way

sSp

ecia

lTh

erap

yU

pper

airw

ays

Year PackConfiguration

Fro

m b

irth

6 ye

ars

+C

hild

ren

an

d a

du

lts

with

add

ition

al b

aby

set/

SMA

RTM

ASK

Bab

y a

lso

suita

ble

from

birt

h

5

PARI SINUSItem No. 028G1000

• PARI LC SPRINT SINUS Nebuliser• PARI SINUS tube system

PARI LC SPRINT SINUSYear PackItem No. 023G2860

n.a.** • Only device for treatment of the paranasal sinuses: Pulsating aerosol transports the medication directly into the paranasal sinuses

• With PARI LC SPRINT nebuliser also suitable for the lower airways (accessories available)

SinusitisSinubronchitis

8

VELOX® JuniorItem No. 055G1101


• VELOX control unit• VELOX membrane nebuliser• Mouthpiece• VELOXcare• Power adapter• Case• SMARTMASK Baby

VELOX Junior Year PackItem No. 055G3110

• Fast – Inhalation in about 3 min.• Quiet – Almost silent• Mobile – Small and battery-powered• As effective as PARI JuniorBOY SX• Extra-soft baby mask


12

PARI JuniorBOY® SX Item No. 085G3301

• Mouthpiece• BABY mask size 2 / BABY bend• PARI LC SPRINT Junior Nebuliser

PARI JuniorBOY Year Pack SItem No. 023G1111

• Faster inhalation than conventional inhalation systems due to 1.6 bar motor• Clinically tested nebuliser system developed specially for children• Fine droplets for small airways• Inhalation possible while lying down

Bronchial asthma/Allergic asthmaAcute and chronic bronchitisAtelectasis or bronchiectasis

15

VELOX®

Item No. 055G1001

• VELOX control unit• VELOX membrane nebuliser• Mouthpiece• VELOXcare• Power adapter• Case

VELOX Year PackItem No. 055G3010

• Fast – Inhalation in about 3 min.• Quiet – Almost silent• Mobile – Small and battery-powered• As effective as PARI BOY SX


12

PARI BOY® SX Item No. 085G3001

• Mouthpiece• Child mask soft• PARI LC SPRINT Nebuliser• Additional red nozzle attachment• LC Interrupter• PIF Control

PARI BOY SX Year PackItem No. 023G8511

• Faster inhalation than conventional inhalation systems due to 1.6 bar compressor• Extra equipment for severe chronic diseases of the airways• Additional nozzle attachment for days of heavy obstruction and mucus production

Bronchial asthma/Allergic asthmaAcute and chronic bronchitisAtelectasis or bronchiectasisPulmonary emphysemaCOPD

14

PARI TurboBOY® SX Item No. 085G3201



• Basic equipment for acute and chronic diseases of the airways• Faster inhalation than conventional inhalation systems due to 1.6 bar compressor• Highly effective, clinically tested nebuliser system


16

PARI mini® Item No. 047G4001



• Small and light inhalation device• Can be used anywhere in the world with the accompanying multi-voltage power adapter


17

PARI BOY® mobile SItem No. 047G1000

• Moutpiece• Child mask soft• PARI LC SPRINT Nebuliser• 12 V vehicle electrical socket• Convenient shoulder bag


• Portable, battery powered compressor nebuliser provides treatment without relying on mains power• Rechargeable battery can be charged anywhere in the world with the accompanying multi-voltage power adapter or even with the

12 V car socket• Carrying case included in the delivery for practical stowage of the device when you travel


13

PARI COMPACT

Item No. 052G1002


– • High PARI quality standard• Clinically tested nebuliser system

Bronchial asthma/Allergic asthmaAcute and chronic bronchitisCOPD

18

eFlow®rapidItem No. 178G1005


– • Special device for severe diseases of the airways with broad treatment spectrum• Short inhalation times• Silent, discreet operation• Lightweight, small and portable• Display provides feedback during inhalation

Cystic fibrosisPrimary ciliary dyskinesia (PCD)

20

Inhalation Devices Target group/Characteristic Indication PageCo

nfig

urat

ion

Fast

Qui

et/m

obile

Dep

osit

ion

in t

he lu

ng

The more dots the more pronounced the corresponding characteristic

* Deposition in the throat** Deposition in the nose and paranasal sinuses

INH

ALA

TIO

N

DEV

ICES

7

Upper AirwaysThe upper airways are the entry portal to the airways. They consist of three areas, all of which are coated with mucus:

• Nose and the paranasal sinuses• Throat• Larynx

Typical pathologies of the upper airways include rhinitis, acute and chronic rhinosinusitis, pharyngitis, laryngitis or croup.

For effective inhalation therapy of the upper airways, a large droplet size is important. This enables the greatest possible quantity of the aerosol to be deposited there.

When it comes to the paranasal sinsues, the challenge is actually getting the aerosol there. The aerosol must pass through the tiny openings (ostia) that connect the nasal cavities to the paranasal sinuses. PARI SINUS with its pulsating aerosol has been developed specially to overcome this hurdle. (see page 8).

You can see our range of inhalation devices for the upper airways on the following pages.

INH

ALA

TIO

N

DEV

ICES

AIRWAYS

Up

per

Air

way

sLo

wer

Air

way

s

Windpipe

Throat

Larynx

Nasalcavities

Nose

Bronchi

8

When it comes to treating sinusitis, specialised nebuliser therapy is called for. Besides providing the known advantages of nebuliser therapy, PARI SINUS generates a pulsating aerosol. In contrast to standard aerosols, pulsating aerosols are able to pass through the ostia and deliver the medication where it is required, to the paranasal sinuses.

PARI SINUS

• Pulsating aerosol effectively delivers the medication and saline to the paranasal sinuses

• Impressive symptom relief and clear improvement in quality of life 1,2

• Suitable for patients with acute and chronic sinusitis as well as those with a concomitant disease of the lower airways

Configuration:

• PARI LC SPRINT SINUS Nebuliser

• PARI SINUS tube system

Technical data:

Alternating current :230 V~ 50 Hz

Pressure: 1.5 bar

Weight: 1.8 kg

Housing dimensions:

(W x H x D) 19.2 x 14.5 x 15 cm

Warranty: 3 years

Item No. 028G1000

Aerosol characteristics:

Total Output Rate: 220 mg/min

MMD: 3.2 μm

Mass fractions < 5 μm:

71 %

Measurement taken with the Malvern Spraytec at 23 °C and 50% relative humidity. Nebulised medium: 0.9% NaCl (5 ml).Jet Flow 4.6 l/min

Useful accessories Item No. Page

PARI LC SPRINT SINUS Year Pack 023G2860 32

PARI LC SPRINT SINUS Nebuliser 023G2800 34

PARI LC SPRINT Nebuliser 023G1001 34

PARI Bag 085E1100 –

Pulsating aerosol for the treatment of sinusitis

1 Geppe N. et al (2009): Nebuliser therapy of rhinosinusitis in Children. Poster presentation ERS2 Hanga D., Baumann I., Rohde S., Schipper J., 83. Jahresversammlung der Deutschen Gesellschaft für HNO, Kopf- und Hals-Chirurgie, oral presentation, 16.-20 May, 2012

Upper airways

9

PARI MONTESOL Nasal Douche and Nasal RinseEffective and Gentle Nasal Rinsing

PARI MONTESOL Nasal Douche Fill volume: 250 ml

PARI MONTESOL Nasal Rinse250 ml concentrated solutionfor 30 applications

Item No. 177G1010

Item No. 177G1020

Ideal preparation for nebuliser treatment with PARI SINUS

Often referred to as nasal douching or lavage, nasal rinsing has been around for a very long time. In fact it has been an integral part of the yoga tradition for thousands of years and is commonly practiced by Yogis all over the world.

PARI MONTESOL Nasal Douche

• Can be boiled to sterilize thus ensuring utmost hygiene

• Compact and easy to hold

• Easy to use PARI MONTESOL Nasal Rinse

• Concentrated saline enriched with soothing dexpanthenol

• Practical bottle that enables exact dosing

Usually performed with a nasal douche and saline solution, nasal rinsing is generally considered to be an effective and well tolerated method of:

• removing dirt and allergens

• removing excess mucous from the nose

• rehydrating dry noses

• removing heavy incrustation after surgery

• preventing & alleviating cold-like symptoms Effectively treating chronic rhinosinusitis is often not possible with rinsing alone. However, it can support and help clear the way to the ostia, the small openings between the nasal cavity and paranasal sinuses. By doing so, it is an ideal preparation for the treatment of rhinosinusitis with PARI SINUS.

INH

ALA

TIO

N

DEV

ICES

11

Lower AirwaysThe lower airways consist of the windpipe and the lungs. The lung, in turn, can be divided into three main constituents:

• Bronchia (diameter 8 – 12 mm)• Bronchioles (diameter 0.4 mm)• Pulmonary alveoli (diameter 50 – 250 µm)

Typical diseases of the lower airways include cough, bronchitis, pneumonia, asthma, COPD and cystic fibrosis. Depending on the disease, the medication has to be effective in different areas of the lung.

Since the lung structures differ so widely in size, it is essential for the inhalation system to produce an aerosol with the right droplet size. Only then can it be ensured the medication is delivered to the part of the lung where it is needed.

We offer a range of inhalation devices for the lower airways. As a result, we can meet this requirement and can provide an individual inhalation therapy for your patients.

You can see our portfolio of inhalation devices for the lower airways on the following pages.

AIRWAYS

Up

per

Air

way

sLo

wer

Air

way

s

Windpipe

Throat

Larynx

Nasalcavities

Nose

Bronchi

INH

ALA

TIO

N

DEV

ICES

12

VELOX® and VELOX® Junior

The VELOX makes life easier by shortening inhalation times and creating more space for the more enjoyable things in life. Its ergonomic design and small number of components help to make operation easier, and the almost noiseless operation guarantees discreet, relaxed treatment. The optional battery operation ensures maximum flexibility, and its very compact size and weight make it the ideal travelling companion.

• Fast, efficient aerosol treatment: approx. 3 min for 2.5 ml inhalation solution (salbutamol ready-to-use nebules)

• Ergonomic design

• Practically noiseless operation

• Maximum mobility


VELOX Year Pack 055G3010 32

VELOX Junior Year Pack 055G3110 32

VELOXcare 055G6100 –

VELOX Cap 055G3500 –

VELOX Junior Cap 055G3510 –

VELOX AC power supply (EU) 055G7100 –

SMARTMASK Baby 055G4500 30

VELOX bag 055G8000 –

Mobile, with modern vibrating membrane technology – for particularly fast and quiet inhalation



MMD: 3.8 μm


74 %

Measurement using laser diffraction (Helos SympaTec) at 23 °C and 50% relative humidity. Nebulised medium: 0.9% NaCl (2.5 ml). Inspiratory flow: 20 l/min.

Configuration:

• Mouthpiece • VELOXcare• VELOX control unit• VELOX membrane nebuliser• Power adapter• Case• VELOX Junior:

+ SMARTMASK Baby

Technical data:

Power plug: 100 – 240 V/50 – 60 Hz (can be used with all mains volt-ages worldwide); Mains-free operation with batteries/rechargeable batteries The device does not have a charging function

Weight: 110 g (without batteries/rechargeable batteries)

Housing dimensions:(W x H x D) 4.5 x 8.0 x 12.5 cm

Warranty: Control unit 2 years

VELOX

Item No. 055G1001

VELOX Junior

Item No. 055G1101

Lowerairways

VELOX Junior® – Available in selected countries only

13

PARI BOY® mobile S

The PARI BOY mobile S is an effective, high-performance inhalation device that can provide treatment without relying on mains power.

A great device for travelling. Its rechargeable battery can be recharged anywhere in the world, even via the 12 V car socket, with the accompanying universal charging power adapter.

• The mobile PARI BOY with rechargeable batteries for inhalation treatment any time, anywhere

• This lightweight among PARI inhalation devices offers efficient treatment with a powerful compressor

• Your reliable companion – at work, at leisure and on the road

Configuration:

• Moutpiece• Child mask soft• PARI LC SPRINT Nebuliser• 12 V vehicle electrical

socket• Convenient shoulder bag

Technical data:

Alternating current :100 – 240 V/50 – 60 Hz

Pressure 1.0 bar

Weight: 520 g*

Housing dimensions:(W x H x D) 8.9 x 4.5 x 14.8 cm*

Warranty: compressor 2 years, rechargeable battery 6 months

Item No. 047G1000



MMD: 3.8 μm


65 %

Measurement with Malvern Mastersizer X at 23 °C and 50% relative humidity. Nebulised medium: 0.9 % NaCl (5 ml). Inspiratory flow 20 l/min.



PARI TurboBOY Year Pack S 023G1011 32

12 V Connection Cable 047G2001 –

AC Adapter 047G2101 –


Portable, battery-powered compressor nebuliser for mobile treatment

* incl. rechargeable battery

INH

ALA

TIO

N

DEV

ICES

4+

14

PARI BOY® SX

The PARI BOY SX is the right device for patients who need particular assistance during treatment and who also might benefit from short inhalation session times. An extensive range of extra equipment makes the PARI BOY SX the versatile device for airway treatment.

• Optional intermittent nebulising for combined physiotherapy

• PARI LC SPRINT Nebuliser with extra nozzle attachment (red) for fine droplets

• With PIF Control – the integrated “training tool” helps patients to learn effective inhalation technique


PARI BOY SX Year Pack 023G8511 32

PARI LC Interrupter 022G1000 30

PARI Filter/Valve Set 041G0500 58

PARI PEP S System 018G4000 46

PARI TRACHEO SET 025G0007 30


Flexible, with variable droplet spectrum and optional intermittent nebulising

Configuration:

• Mouthpiece• Child mask soft• PARI LC SPRINT Nebuliser• LC Interrupter• Additional red nozzle

attachment• PIF Control

Technical data:

Alternating current :230 V ~ 50 Hz

Pressure: 1.6 bar

Weight: 1.7 kg

Housing dimensions:

(W x H x D) 19.2 x 14.5 x 15 cm

Warranty: 4 years

Item No. 085G3001


Blue nozzle attachment:


MMD: 3.5 μm


67 %

Red nozzle attachment


MMD: 2.2 μm


89 %

Measurement with Malvern Mastersizer X at 23 °C and 50 % relative humidity. Nebulised medium: 0.9 % NaCl (5 ml). Inspiratory flow 20 l/min.

With PIF Control! see page 27

Lowerairways

4+

15

This is why the PARI JuniorBOY SX is a good choice for the inhalation treatment of babies from the first month of life and infants. It produces particularly fine droplets, and its equipment is specially adapted to the needs of small patients. This makes the PARI JuniorBOY SX ideal for providing the most efficient treatment possible for babies and infants as young as one month.

• Inhalation time: less than 7 min for 2.5 ml inhalation solution (salbutamol ready-to-use nebules)

• Equipment for babies as young as one month old: BABY mask, BABY bend (BABY mask and BABY bend must always be used together)

• PARI LC SPRINT Junior Nebuliser with fine droplets for the smaller airways of babies and infants

Configuration:

• Mouthpiece• BABY mask size 2 /

BABY bend• PARI LC SPRINT Junior

Nebuliser

Technical data:

Alternating current 230 V ~ 50 Hz

Pressure: 1.6 bar

Weight: 1.7 kg

Housing dimensions:

(W x H x D) 19.2 x 14.5 x 15 cm

Warranty: 4 years

Item No. 085G3301



MMD: 2.9 μm


76 %

Measurement with Malvern Mastersizer Xat 23 °C and 50x% relative humidity.Nebulised medium: 0.9 % NaCl (5 ml).Inspiratory flow: 12 l/min (children)


PARI LC SPRINT Junior Nebuliser 023G1101 34

PARI JuniorBOY Year Pack S 023G1110 32

Sputum Trap 041G0530 30





BABY mask incl. BABY bend size 0 041G0700 29




PARI SMARTMASK Kids 078G5000 30

PARI JuniorBOY® SXWith fine droplets – specially designed to treat babies and infants

0+

INH

ALA

TIO

N

DEV

ICES

16

PARI TurboBOY® SX

The PARI TurboBOY SX is ideally suited for all patients aged 4 and older who want fast, uncomplicated inhalation treatment. The PARI LC SPRINT Nebuliser ensures that a sufficient quantity of medication reaches the lungs even with short inhalation times. Easy operation makes inhalation easy, even for children.

• Inhalation time: less than 5 min for 2.5 ml inhalation solution (salbutamol ready-to-use nebules)

• PARI LC SPRINT Nebuliser for efficient lung deposition even with short inhalation times

• With masks for children and adults

Configuration:


Technical data:

Alternating current:230 V ~ 50 Hz

Pressure: 1.6 bar

Weight: 1.7 kg

Housing dimensions:

(W x H x D) 19.2 x 14.5 x 15 cm

Warranty: 4 years

Item No. 085G3201







PARI TRACHEO SET 025G0007 30


PARI SMARTMASK 041G0730 30

The allrounder for treating the lower airways of patients aged 4 and older


Blue nozzle attachment:


MMD: 3.5 μm


67 %

Measurement with Malvern Mastersizer X at 23 °C and 50 % relative humidity. Nebulised medium: 0.9 % NaCl (5 ml). Inspiratory flow 20 l/min.

4+

17

PARI mini ®

Small, light and quiet the PARI mini comes complete with a durable, highly efficient LC SPRINT Nebuliser, mouthpiece, child mask, tubing and multi-voltage power adapter.

• Can be used from multi-voltage mains cable or from car cigarette lighter / 12 V connection cable

• Can be used for all drugs approved for inhalation


12 V connection tubing 047G2001 –

PARI Storage bag 047E3000 –


Reliable nebuliser therapy for diseases of the lungs



MMD: 3.8 μm


65 %

Measurement with Malvern Mastersizer X at 23 °C and 50% relative humidity. Nebulised medium: 0.9% NaCl (5 ml). Inspiratory flow 20 l/min.

Configuration:


Item No. 047G4001

Technical data:

Alternating current:100 – 240 V/50 – 60 Hz

Pressure: 1.0 bar

Weight: 360 g

Housing dimensions:

(W x H x D) 4.5 x 8.9 x 11.3 cm

Warranty: 2 years

4+


INH

ALA

TIO

N

DEV

ICES

18

For patients who want to buy a cost-effective, robust device, the PARI COMPACT offers the customary reliability and PARI quality at an affordable price.

• High quality compressor from PARI

• With clinically proven PARI LC PLUS Nebuliser

• Easy to use and clean



MMD: 3.9 μm


64 %

Measurement with Malvern Mastersizer Xat 23 °C and 50 % relative humidity.Nebulised medium: 0.9 % NaCl (5 ml).Inspiratory flow 20 l/min.


PARI LC PLUS Nebuliser 022G8107 28


PARI PEP System I 018G6101 46

PARI PEP System II 018G6201 46



PARI COMPACTProven effective in the treatment of diseases of the lower airways

Configuration:


Item No. 052G1002

Technical data:

Alternating Current 220 – 240 V/ ~ 50 Hz

Pressure: 1.0 bar

Weight: 1.2 kg

Housing dimensions:

(W x H x D) 14 x 10 x 16 cm

Warranty: 2 years

Lowerairways


With additional baby set also suitable from birth

4+

19

Special TreatmentFor patients with chronic diseases of the airways, like cystic fibrosis, inhalation therapy is an indispensable part of their treatment. These patients typically perform several inhalation sessions a day, which takes up an enormous amount of their time.

With these patients in mind, we have developed an inhalation device that reduces inhalation times by as much as 65% depending on the medication: the eFlow®rapid. The base unit, the eBase®Controller, can be used with the eFlow®rapid nebuliser as well as certain drug-specific nebulisers.

You will find more information on the next two pages.

eFlow®rapidItem No. 178G1005see page 20

INH

ALA

TIO

N

DEV

ICES

20

The eFlow®rapid nebuliser system is an innovative device for the treatment of airway diseases. During its development, particular care was taken to respond to patients' needs for efficient, safe, and above all fast inhalation treatment.

• Short inhalation times

• Noiseless operation for discreet use

• Lightweight, small, portable – runs on mains power or batteries

• Easy to clean, disinfectable – offers highest standards of hygiene

• Display provides feedback during inhalation



MMD: 4.1 μm


69 %

Measurement using laser diffraction (Helos SympaTec) at 23 °C and 50 % relative humidity. Nebulised medium: 0.9 % NaCl (4 ml). Inspiratory flow: 20 l/min.Can fluctuate depending on used drug and aerosol generator.


eFlow rapid nebuliser* 678G8222 –

eFlow rapid aerosol head* 678B2620 –


Filter pads, pack of 30 041B0522 –



SMARTMASK Baby (babies weighing 2.5 kg or more) 078G5026 30

SMARTMASK Kids 078G5000 30

PARI SMARTMASK 041G0730 30

eFlow®rapid nebuliser systemModern inhalation treatment – twice as fast!

Configuration:


Item No. 178G1005

* The “eFlow rapid nebuliser handset” and the “eFlow rapid aerosol head” are compatible with both the eBase Controller (blue controller with display) and the turquoise control unit.

Special Therapy

From 2 years, with additional SMARTMASK® Baby also suitable from birth

2+

21

The eFlow ®rapid nebuliser – for use of approved inhalation solutions such as:• Colistimethate sodium• Tobramycin• Dornase alfa• Hypertonic saline solution

Medication-specific nebulisers such as:• Altera® for Cayston®

• Tolero® for Vantobra®

• Zirela® for Quinsair®

eFlow®rapid Tolero®

1. Seemann S, Hug M, Lichtinghagen R, Schmitt A, Tservistas M, Waldner R, Knoch M: Improving Aerosol Drug Delivery in CF therapy; 28th ECFC, Crete Greece; June 22th – 26th 20052. Keller M, Brendel E, Luithlen A, Bruendl K, Mueller D, Tservistas M, Schierholz J, Denk O: Investigation of Colifin, 1 and 2 million I.U. Colistimethate Sodium (CMS) for aerosolization in the eFlow rapid and PARI LC Sprint nebuliser; 33rd ECFC, Valencia Spain; June 16th – 19th 2005

Up to 65 % shorter nebulising time with eFlow®rapid 1,2

12

10

8

6

4

2

0Tobramycin300 mg/5 ml

Dornase alfa2.5 ml

Colistin 1 Mio IU/3 ml

Colistin 2 Mio IU/4 ml

Jet nebulisers eFlow rapid nebuliser

Neb

ulis

atio

n tim

e [m

in]

Technical data:

Nebuliser principle:Perforated vibrating membrane;Vibration frequency: 117 kHz

Operation with standard battery or rechargeable battery:At least 90 minutes of operation with fully charged rechargeable batteries

Power adapter: 100 – 240 V, 50/60 Hz

Nebuliser weight: ~ 55 g

Total weight: ~ 300 g

Min. fill volume: 2.0 ml

Max. fill volume: 6.0 ml

The eBase®Controller is compatible with:

INH

ALA

TIO

N

DEV

ICES

23

The nebuliser generates the aerosol, and is therefore the central component of the entire inhalation system. To ensure the aerosol delivers the greatest possible effect where it is needed, an aerosol spectrum with the most suitable droplet size must be generated.

We offer two nebuliser families:

• The PARI LC SPRINT Family: with a range of nozzle attachments, suitable for both the upper and lower airways

• The PARI LC PLUS Nebuliser: proven nebuliser for delivering medication to the central area of the lung

Since inhalation speed affects medication deposition, we have built a breath-sensing feedback system – PIF Control – into certain PARI LC SPRINT nebulisers. Details of these are on page 27.

To guarantee a consistently effective inhalation therapy, we recommend replacing the nebuliser once a year. For a hassle-free replacement, a convenient year pack is available for every PARI inhalation device. Besides the nebuliser, it contains a connection tube and an air filter (see overview on page 31).

Our nebulisers can also be purchased separately.

Nebulisers

NEB

ULI

SER

S

2424

Low

er a

irw

ays

Up

per

air

way

sWhich nebuliser is right?

PARI LC SPRINT ® Tracheo

2525

Oro

ph

aryn

gea

l re

gio

nPa

ran

asal

si

nu

ses

Inte

rmed

iate

reg

ion

Peri

ph

eral

re

gio

n

Baby Child Adult

Item No. 023G1101

Page 34

PARI LC SPRINT ® SINUS Nebuliser

PARI LC SPRINT ® XLent Nebuliser

PARI LC SPRINT ® STAR Nebuliser

Item No. 023G2800

see page 34

Item No. 023G1250

Page 34

Item No. 023G1801

Page 34

Depends on the age of the patient and the deposition site

PARI LC SPRINT ® NebuliserPARI LC SPRINT ® Junior Nebuliser

PARI LC SPRINT ® Baby Nebuliser

Item No. 023G1001

Page 34

Item No. 023G1400 -1403

Page 34

PARI LC SPRINT ® Tracheo

PARI LC PLUS® Nebuliser

Item No. 022G8000

Page 28

Item No. 023G1080

Page 34

NEB

ULI

SER

S

26

PARI LC SPRINT® Family

The nebulisers of the PARI LC SPRINT family, equipped with various nozzle attachments to generate different droplets, offer solutions adapted to the individual needs of users according to indication and age group. The PARI LC SPRINT Nebulisers consist of a small number of individual components, so they can be assembled and disassembled quickly and easily. This also makes them easy to clean thoroughly. Their user friendly design is also intended to make inhalation treatment as comfortable as possible for the user while ensuring maximum efficiency.

• Different nozzle attachments produce different aerosol spectra

• Targeted deposition in the desired region of the airways

• Can be used by a wide age range of patients and a large variety of indications

Nebulisers with individual droplet size for each indication

OrangeNozzle attachment

Pulsed droplets for efficient deposition in the paranasal sinuses

TransparentNozzle attachment

XL droplets for deposition in the upper airways

BlueNozzle attachment

Droplets for efficient deposition in the central region of the lungs in older children and adults

YellowNozzle attachment

Small droplets for small airways in babies and children

RedNozzle attachment

Smallest possible drop-lets for the peripheral region of the lungs or for babies one month old and older and for premature babies

Lower airways Upper airways

27

PARI PIF Control

Slow inhalation aids effective deposition of active substances into the lung. In order to achieve the best possible breathing cycle for high lung deposition, PARI has developed a breath sensing feedback system – the PIF Control System (PIF = Peak Inspiratory Flow). With this system, if the patient breathes in too quickly the inspiratory valve platelet reduces the size of the aperture in the nebuliser chamber. The patient perceives this as resistance – a sign they should exhale and then inhale more slowly during the next breath, so they do not feel the resistance anymore.

PARI PIF Control is available in selected PARI nebulisers.

Training for effective inhalation

Breathing in quickly Breathing in slowly

Laube et al. J. AllergyClin Immunol 89(2):510–518, 1992

Lowerairways

PIF CONTROL

Patentedsystem

Pipe

Aperture

NEB

ULI

SER

S

28


in combination with PARI COMPACT


MMD: 3.9 μm


64 %

Measurement with Malvern Mastersizer Xat 23 °C and 50 % relative humidity.Nebulised medium: 0.9 % NaCl (5 ml).Inspiratory flow 20 l/min.


PARI PEP System I 018G6101 46

PARI PEP System II 018G6201 46


PARI LC PLUS® Nebuliser

The PARI LC PLUS Nebuliser has proven its efficacy in many clinical trials, and for many years it has been acknowledged as the “GOLD Standard” for nebuliser therapy for diseases of the lower airways, such as asthma, COPD or bronchitis.

The small number of components makes it easy to use and clean thoroughly. Medication losses in the exhalation phase are minimised due to the integrated valve system.

• Proven nebuliser with valve system

• For deposition in the central region of the lungs

Tested and proven in many clinical trials

Lower airways

PARI LC PLUS Nebuliser

Item No. 022G8000

29

Masks & Mouthpieces for Nebulisers

Item No. 041G0700

Item No. 041G0701

Item No. 041G0702

Item No. 041G0703

Item No. 041G0740

Item No. 041G0741

Item No. 012E1720

Item No. 022E3050

Item No. 041E0701

PARI BABY mask size 0 with BABY bend for premature babies

PARI BABY mask size 1 with BABY bend for approx. 0 – 1 year

PARI BABY mask size 2 with BABY bend for approx. 1 – 3 years

PARI BABY mask size 3 with BABY bend for approx. 3 years and older

Adult mask soft sterilisable with mask stabiliser

Child mask soft “Spiggy”sterilisable with mask stabiliser

PARI Mouthpiece without expiratory valve for Filter/Valve Set and PARI PEP Systems I, II and S

PARI universal mouthpiece for children and adults

BABY bendis needed for BABY masks, BABY masksmust always be used together with the BABY bend

NEB

ULI

SER

S

30

Item No. 055G4500

Item No. 078G5026

PARI SMARTMASK® Babyfor VELOX/VELOX Junior, up to about 2 – 3 years

for eFlow®rapid including bend, for babies weighing 2.5 kg or more

Item No. 078G5000

Item No. 041G0730

Item No. 041G0749

Item No. 041G0748

Item No. 041G0540

Item No. 023G2840

Item No. 025G0007

Item No. 022G1000

Item No. 041G0530

SMARTMASK® Kidsfor children aged about 2 years and older

PARI SMARTMASK®

for adults including bend (45 degree)

Mask stabiliser (for PARI adult mask soft)stabiliser for sterilisation in the autoclave, pack of 5

Mask stabiliser(for PARI child mask soft) stabiliser for sterilisingin the autoclave, pack of 5

PARI Application set consisting of: Adult mask soft,mouthpiece (without expiratory valve) and nasal joining piece

PARI LC SPRINT® SINUS Application set45-degree bend, nasal joining piece,vibration connection, nasal plug

PARI TRACHEO SET tracheostoma mask made from soft, latex-free silicone, extension tube

PARI LC Interrupter enables intermittent nebulising

Sputum trap

Masks & Mouthpieces for Nebulisers

31

PARI YEAR PACKS –

If used and cleaned frequently, like any other plastic part the nebuliser is also susceptible to a certain amount of wear. Over time, this can cause for example changes in the aerosol spectrum and impair therapeutic efficacy. In order to guarantee the long-term effectiveness of inhalation treatment, certain components of the nebuliser device should be replaced once a year. Recommend or prescribe the appropriate PARI Year Pack for your patients: These practical complete sets contain everything to ensure that the PARI nebuliser device will remain in top condition for a full year: nebuliser, connection tubing and air filter – each designed to fit any PARI nebuliser device perfectly. This way, the nebuliser device is well maintained and can provide outstanding service for a long time.

To assure consistent high quality nebuliser performance

*Please note: There is no Year Pack for PARI COMPACT available, but the PARI LC PLUS Nebuliser which can be used with PARI COMPACT can be bought seperately.

PARI LC SPRINT SINUS Year Pack 4

VELOX Year Pack 4 4

VELOX Junior Year Pack 4 4

PARI BOY SX Year Pack 4 4 4 4 4 4

PARI JuniorBOY Year Pack S 4 4 4 4 4 4

PARI TurboBOY Year Pack S 4 4 4 4 4 4

PARI LC PLUS Nebuliser 4

PAR

I SI

NU

S

VEL

OX

VEL

OX

Jun

ior

PAR

I BO

Y m

obile

S

PAR

I BO

Y S

X

PAR

I Ju

nior

BOY

SX

PAR

I Tu

rboB

OY

SX

PAR

I m

ini

PAR

I C

OM

PAC

T*Which year pack goes with which PARI inhalation device?

NEB

ULI

SER

S

32

VELOX® Junior Year PackItem No. 055G3110

VELOX Junior membrane nebuliserwith mouthpiece

TOR: 497 mg/minMMD: 3.8 μmMass fractions < 5 μm: 74 %

VELOX JuniorItem No. 055G1101 see page 12

VELOX control unit

PARI JuniorBOY® Year Pack SItem No. 023G1111

PARI LC SPRINT Junior Nebuliser(yellow nozzle attachment)Universal mouthpiecelong connection tubing (f/m)*Filters for PARI BOY compressors

in combination with the PARI JuniorBOY SX 2:TOR: 370 mg/minMMD: 2.9 μmMass fractions < 5 μm: 76 %

PARI JuniorBOY SXItem No. 085G3301 see page 15

all PARI devicesexcept PARI COMPACT

VELOX® Year PackItem No. 055G3010

VELOX membrane nebuliser withmouthpiece


VELOXItem No. 055G1001 see page 12

VELOX control unit

PARI BOY® SX Year PackItem No. 023G8511

PARI LC SPRINT Nebuliser(blue nozzle attachment)Red nozzle attachmentUniversal mouthpieceConnection tubing (f/m)*Filters for PARI BOY compressorsPIF Control

yes in combination with the PARI TurboBOY SX/BOY SX 3:Blue nozzle attachment: TOR: 600 mg/min MMD: 3.5 μm Mass fractions < 5 μm: 67 %Red nozzle attachment: TOR: 450 mg/min MMD: 2.2 μm Mass fractions < 5 μm: 89 %

PARI BOY SXItem No. 085G3001 see page 14


PARI TurboBOY® Year Pack SItem No. 023G1011

PARI LC SPRINT Nebuliser(blue nozzle attachment)Universal mouthpieceConnection tubing (f/m)*Filters for PARI BOY compressors

in combination with the PARI TurboBOY SX/BOY SX 3:TOR: 600 mg/minMMD: 3.5 μmMass fractions < 5 μm: 67 %

PARI TurboBOY SXItem No. 085G3201see page 16PARI BOY mobile SItem No. 047G1000see page 13 PARI miniItem No. 047G4001 see page 17


Produktname Configuration PIF Aerosol characteristics Reorder set for Combinable Control the following devices with

PARI LC SPRINT® SINUS Year PackItem No. 023G2860

PARI LC SPRINT SINUS NebuliserPARI SINUS Tube systemFilter

in combination with the PARI SINUS compressor 1:TOR: 220 mg/min MMD: 3.2 μm Mass fractions < 5 μm: 71 %

PARI SINUSItem No. 028G1000see page 8

–

* female/male,

Year Packs

33

VELOX® Junior Year PackItem No. 055G3110

VELOX Junior membrane nebuliserwith mouthpiece


VELOX JuniorItem No. 055G1101 see page 12

VELOX control unit

PARI JuniorBOY® Year Pack SItem No. 023G1111

PARI LC SPRINT Junior Nebuliser(yellow nozzle attachment)Universal mouthpiecelong connection tubing (f/m)*Filters for PARI BOY compressors




VELOX® Year PackItem No. 055G3010

VELOX membrane nebuliser withmouthpiece


VELOXItem No. 055G1001 see page 12

VELOX control unit

PARI BOY® SX Year PackItem No. 023G8511

PARI LC SPRINT Nebuliser(blue nozzle attachment)Red nozzle attachmentUniversal mouthpieceConnection tubing (f/m)*Filters for PARI BOY compressorsPIF Control

yes in combination with the PARI TurboBOY SX/BOY SX 3:Blue nozzle attachment: TOR: 600 mg/min MMD: 3.5 μm Mass fractions < 5 μm: 67 %Red nozzle attachment: TOR: 450 mg/min MMD: 2.2 μm Mass fractions < 5 μm: 89 %

PARI BOY SXItem No. 085G3001 see page 14


PARI TurboBOY® Year Pack SItem No. 023G1011

PARI LC SPRINT Nebuliser(blue nozzle attachment)Universal mouthpieceConnection tubing (f/m)*Filters for PARI BOY compressors


PARI TurboBOY SXItem No. 085G3201see page 16PARI BOY mobile SItem No. 047G1000see page 13 PARI miniItem No. 047G4001 see page 17


Produktname Configuration PIF Aerosol characteristics Reorder set for Combinable Control the following devices with

PARI LC SPRINT® SINUS Year PackItem No. 023G2860

PARI LC SPRINT SINUS NebuliserPARI SINUS Tube systemFilter

in combination with the PARI SINUS compressor 1:TOR: 220 mg/min MMD: 3.2 μm Mass fractions < 5 μm: 71 %


–

1 Measurement with the Malvern Spraytec (calculated using the Mie model) at 23 °C and 50 % relative humidity. Nebulised medium: 0.9 % NaCl (5 ml). Jet Flow 4.6 l/min2 Inspiratory flow 20 l/min, measurement with Malvern Mastersizer X (calculated according to the Fraunhofer model) at 23 °C and 50 % humidity. Nebulised medium: 0.9 % NaCl (5 ml). Inspiratory flow 12 l/min. Measured with child’s inspiratory flow.3 Inspiratory flow 20 l/min, measurement with Malvern Mastersizer X (calculated according to the Fraunhofer model) at 23 °C and 50 % humidity. Nebulised medium: 0.9 % NaCl (5 ml).

NEB

ULI

SER

S

34

Nebulisers

* female/male, ** female/female

PARI LC SPRINT® XLent NebuliserItem No. 023G1801

Transparent nozzle attachmentTube system (f/f)**Adapter for use withall PARI compressors

in combination with the PARI XLent compressor 1:TOR: 875 mg/minMMD: 7.3 μmMass fractions < 5 μm: 65.4 %Mass fractions > 7 μm: 53 %

– With all PARI devices

PARI LC SPRINT® SINUS NebuliserItem No. 023G2800

Orange nozzle attachmentBend (45 degree)Vibration connectionNasal joining pieceNasal plug

in combination with the PARI SINUS compressor 2:TOR: 220 mg/minMMD: 3.2 μmMass fractions < 5 μm: 71 %


–

PARI LC SPRINT® NebuliserItem No. 023G1001

Blue nozzle attachmentConnection tubing (f/m)*Universal mouthpiece


PARI TurboBOY SXItem No. 085G3201 see page 16PARI BOY mobile SItem No. 047G1000 see page 14

With all PARI devicesexcept PARI COMPACTand PARI CENTRAL

PARI LC SPRINT® TracheoItem No. 023G1080

Blue nozzle attachmentPARI LC tracheoadapterLong connection tubing (f/f)**adapter

in combination with the PARI CENTRAL(compressed air source 1.6 bar) 3:TOR: 600 mg/minMMD: 3.5 μmMass fractions < 5 μm: 67 %


PARI LC SPRINT® Junior NebuliserItem No. 023G1101

Yellow nozzle attachmentLong connection tubing (f/m)*Universal mouthpiece




PARI LC SPRINT® BABY NebuliserItem No. see Product variants below

Red nozzle attachmentBABY bendLong connection tubing (f/m)*BABY mask, PIF Control

yes in combination with the PARI BOY SX 5:TOR: 150 mg/minMMD: 2.5 μmMass fractions < 5 μm: 82 %

– With all PARI devicesexcept PARI COMPACTand the PARI CENTRAL

PARI LC SPRINT® STAR NebuliserItem No. 023G1250

Red nozzle attachmentincl. connection tubing (f/m)*Universal mouthpiecePIF Control


– With all PARI devicesexcept PARI COMPACTand PARI CENTRAL

PARI LC PLUS® NebuliserItem No. 022G8107

Universal mouthpieceConnection tubing(Adapter) only with 022G8107Filter + filter changer

in combination with the PARI COMPACT 3:TOR: 418 mg/minMMD: 3.9 μmMass fractions < 5 μm: 64 %

PARI COMPACT Item No. 052G1002see page 18

With all PARI devices

With mask size 0Item No. 023G1400

for premature babies


for age approx. 0 – 1 year


for age approx. 1 – 3 years


for approx. 3 years and older

Product name Configuration PIF Aerosol characteristics Component of Combinable with Control PARI devices following devices

35

1 Measurement with the Malvern Spraytec (calculated using the Mie model) at 23 °C and 50 % relative humidity. Nebulised medium: 0.9 % NaCl (6 ml). Inspiratory flow 20 l/min.2 Measurement with the Malvern Spraytec (calculated using the Mie model) at 23 °C and 50 % relative humidity. Nebulised medium: 0.9 % NaCl (5 ml). Jet Flow 4.6 l/min3 Inspiratory flow 20 l/min, measurement with Malvern Mastersizer X (calculated according to the Fraunhofer model) at 23 °C and 50 % humidity. Nebulised medium: 0.9 % NaCl (5 ml).4 Measurement with Malvern Mastersizer X (calculated according to the Fraunhofer model) at 23 °C and 50 % humidity. Nebulised medium: 0.9 % NaCl (5 ml). Inspiratory flow 12 l/min. Measured at a child’s inspiratory flow rate.5 Measurement with Malvern Mastersizer X (calculated according to the Fraunhofer model) at 23 °C and 50 % humidity. Nebulised medium: 0.9 % NaCl (5 ml). Inspiratory flow 6 l/min. Measured at a baby’s inspiratory flow rate. TOR: Total Output Rate / MMD: Median Mass Diameter

PARI LC SPRINT® XLent NebuliserItem No. 023G1801

Transparent nozzle attachmentTube system (f/f)**Adapter for use withall PARI compressors

in combination with the PARI XLent compressor 1:TOR: 875 mg/minMMD: 7.3 μmMass fractions < 5 μm: 65.4 %Mass fractions > 7 μm: 53 %


PARI LC SPRINT® SINUS NebuliserItem No. 023G2800

Orange nozzle attachmentBend (45 degree)Vibration connectionNasal joining pieceNasal plug

in combination with the PARI SINUS compressor 2:TOR: 220 mg/minMMD: 3.2 μmMass fractions < 5 μm: 71 %


–

PARI LC SPRINT® NebuliserItem No. 023G1001

Blue nozzle attachmentConnection tubing (f/m)*Universal mouthpiece


PARI TurboBOY SXItem No. 085G3201 see page 16PARI BOY mobile SItem No. 047G1000 see page 14


PARI LC SPRINT® TracheoItem No. 023G1080

Blue nozzle attachmentPARI LC tracheoadapterLong connection tubing (f/f)**adapter

in combination with the PARI CENTRAL(compressed air source 1.6 bar) 3:TOR: 600 mg/minMMD: 3.5 μmMass fractions < 5 μm: 67 %


PARI LC SPRINT® Junior NebuliserItem No. 023G1101

Yellow nozzle attachmentLong connection tubing (f/m)*Universal mouthpiece




PARI LC SPRINT® BABY NebuliserItem No. see Product variants below

Red nozzle attachmentBABY bendLong connection tubing (f/m)*BABY mask, PIF Control


– With all PARI devicesexcept PARI COMPACTand the PARI CENTRAL

PARI LC SPRINT® STAR NebuliserItem No. 023G1250

Red nozzle attachmentincl. connection tubing (f/m)*Universal mouthpiecePIF Control


– With all PARI devicesexcept PARI COMPACTand PARI CENTRAL

PARI LC PLUS® NebuliserItem No. 022G8107

Universal mouthpieceConnection tubing(Adapter) only with 022G8107Filter + filter changer

in combination with the PARI COMPACT 3:TOR: 418 mg/minMMD: 3.9 μmMass fractions < 5 μm: 64 %

PARI COMPACT Item No. 052G1002see page 18

With all PARI devices


for premature babies


for age approx. 0 – 1 year


for age approx. 1 – 3 years


for approx. 3 years and older

Product name Configuration PIF Aerosol characteristics Component of Combinable with Control PARI devices following devices

NEB

ULI

SER

S

37

Holding Chamber„The prescribing physician should ensure that spacers or holding chambers are used when prescribing steroid metered dose inhalers to prevent adverse effects in the oropharyngeal region and absorption via the gut.” 1

When a medication spray is used, the patient must inhale at exactly the same time as the spray is released. Such coordination is difficult, particularly for children and often for the elderly too. As a result, a considerable amount of the medication might be lost on the way to the lungs.

Even if coordination is mastered flawlessly, a holding chamber can help to transport a higher dose of medication to the lungs. This helps to reduce side effects from medication in the mouth and throat.

[1] Laube B et al. 2011; Eur Respir J; 37(6):1308-31

HO

LDIN

G

CH

AM

BER

38

The antistatic holding chamber VORTEX helps to minimise these disadvan-tages. The MDI is triggered into the VORTEX. The patient can then inhale the medication from the holding chamber in their own time. The need to ‘press and inhale simultaneously‘ is minimised and more medication reaches the lung, making the therapy as a whole safer and more effective.

VORTEX®

Medication sprays or MDIs are often used to treat respiratory diseases such as asthma or COPD. The principle of a MDI is that you ‘press and inhale simultaneously’. For some patients like children and the elderly, getting this coordination right can be difficult. Poor coordination results in less medication reaching the lung and being deposited in the mouth and throat instead. The positive effect of the therapy can be reduced and undesirable side effects can result.

• Antistatic metal chamber helps to ensure reliable dosage (1)

• Universal adapter for all popular metered dose inhalers (2)

• Visual control for monitoring spray release (3)

• Protective cap for extra hygiene protection

• Cyclone twist principle supports the transport of small aerosol droplets

• Can be disinfected at home

• Can be disinfected and sterilised in hospitals

The antistatic holding chamber – small, robust and effective.

VORTEX

Item No. 051G5000

Item No. 051G5001

The VORTEX® grows with you:

From infants to adults, the VORTEX can be adapted to the age group and needs of each individual patient with a range of face masks.

2

13

39

VORTEX®

Product variations

Item No. 051G5101

Item No. 041G0712

Item No. 051G0740

Item No. 041G0714

Item No. 051G5000

Item No. 051G5001

Item No. 051G5040

Item No. 051G5041

Item No. 051G5020

Item No. 051G5021

Item No. 051G5060

Item No. 051G5061

Useful accessories

VORTEX® 4 years and older

VORTEX® with baby mask “Ladybug”0 – 2 years

VORTEX® with child mask ”Frog”

2 years and older

Baby mask “Ladybug”0 – 2 years

VORTEX® Mouthpiece Pack of 10

VORTEX® with adult mask

Child mask “Frog”2 years and older

Adult mask soft with mask connector

HO

LDIN

G

CH

AM

BER

40

Lower airways

This application can be performed by patients without difficulty, simply by attaching the adapter to the mouthpiece and connecting it to the tracheal cannula. After the metered dose inhaler is started, the medication can be inhaled calmly and safely.

VORTEX® Tracheo

VORTEX Tracheo, the antistatic holding chamber with tracheo adapter, enables tracheotomised patients with a tracheal cannula to use metered dose inhalers – effective and convenient.

• Easy to use

• Fast, direct delivery via a 15 mm tracheal cannula

• Confident hygiene: Can be disinfected and sterilised at 134º C

VORTEX Tracheo

Item No. 051G5080

The antistatic holding chamber for tracheotomy patients

Saline SolutionsInhaling saline solution is one of the oldest methods for treating diseases of the airways. Whether it be in the form of a seaside climate, salt baths, climatic health resorts or modern inhalation devices: breathing healthy air and healing mist are proven methods for preventing, nursing, alleviating and treating affected airways.

Saline solutions for inhalation are divided into two groups:

• Isotonic saline solutions with a salt content of 0.9%• Hypertonic saline solutions with a salt content of 1% and more

The effects of these two forms of saline solution differ as follows:

• Isotonic saline solutions moisturise the airways• Hypertonic saline solutions promote secretion mobilisation, the more

hypertonic the saline solution, the stronger the mobilisation effect

On the following pages you will find the saline solutions offered by PARI.

SALI

NE

SOLU

TIO

NS

42

PARI NaCl Inhalation Solution

• Moisturises the airways

• For infants, children and adults

• Sterile and preservative-free

For cold infections or as a carrier solution

For natural rehydration and cleaning of the airways or as a carrier solution for medication, PARI NaCl Inhalation solution offers a wide range of applications and is important as a means of preventing diseases caused by dry airways. A favorable secondary treatment for colds and airway infections.

The PARI NaCl Inhalation solution is also especially effective in supporting the airways in problematic environmental conditions involving heavy dust, tobacco smoke, air-conditioned rooms or dry air.

Inhalation with 0.9 % isotonic saline solution is effective for any age group in preventing, managing and treating diseases of the airways.

PARI NaCl Inhalation solution20 x 2.5 ml ampoules NaCl (0.9 %)– sterile


Item No. 077G0000

Item No. 077G0003


Item No. 077G0006

Isotonic (NaCl 0.9 %)


43

MucoClear® 3 % Inhalation Solution

• Loosens mucus gently and effectively

• Can have beneficial effects on the course of the disease



For acute bronchiolitis, bronchitis and cystic fibrosis

A Cochrane Review 1 recommends hypertonic saline solution (3 % – 7 %) for cystic fibrosis

• Sufficient evidence of safety

• Well-tolerated

• Fewer exacerbations – greater quality of life

The US clinical practice guidelines for bronchiolitis 2 recommend nebulised hypertonic saline (3 %) to infants and children hospitalized for bronchiolitis.

A Cochrane Review 3 recommends nebulised 3 % saline may reduce the length of hospital stay among infants hospitalized with non-severe acute viral bronchiolitis.

MucoClear 3 % loosens mucus gently and effectively in diseases of the airways with heavy secretion formation. It is recommended for cystic fibrosis and can be beneficial in the case of acute viral bronchi-olitis and bronchitis. The three-percent hypertonic saline solution can also be used by infants and small children as well as by people with sensitive airways.

MucoClear 3 %Inhalation solution20 x 4 ml ampoules NaCl (3 %) – sterile

MucoClear 3%Inhalation solution60 x 4 ml ampoules NaCl (3 %) – sterile

Item No. 077G5000

Item No. 077G5003

1 Wark P., McDonald VM., Cochrane Database Syst Rev 2009 (23): CD0015062 Ralston SL., Pediatrics 2014 (134):e14743 Zhang L.,Mendoza-Sassi RA., Cochrane Database Syst Rev 2013 (7):CD006458

Hypertonic (NaCl 3 %)


SALI

NE

SOLU

TIO

NS

44

MucoClear® 6 % Inhalation Solution

• Loosens mucus effectively, making clearance by coughing easier



For cystic fibrosis and bronchiectasis

Cochrane Review 1 recommends hypertonic saline solution (3 % – 7%) for cystic fibrosis

• Sufficient evidence of safety

• Well-tolerated

• Fewer exacerbations – greater quality of life

The guidelines of the British Thoracic Society (BTS) 4 recommend hypertonic saline solution for bronchiectasis as part of the physiotherapy programme

• Increased sputum volume

• Reduced viscosity of sputum

• Easier clearance by coughing

As a highly concentrated hypertonic saline solution, MucoClear 6% loosens mucus powerfully and eases clearance by coughing. Guide-lines recommend hypertonic saline solution for cystic fibrosis and confirm its efficacy and safety. Additionally, it can be beneficial in the case of bronchiectasis.



Item No. 077G3000

Item No. 077G3001

Hypertonic (NaCl 6 %)

2 Wark P., McDonald VM., Cochrane Database Syst Rev 2009 (23): CD0015064 Pasteur MC., Bilton D., British Thoracic Society guideline for non-CF bronchiectasis. Thorax. 2010;65:1-58.


PEP SystemsWith both acute and chronic diseases of the lower airways, secretion mobilisation and clearance by coughing can be very difficult, particularly with stubborn mucus. PEP therapy is an established, effective method for dislodging difficult to clear mucus from the bronchia. PEP stands for Positive Expiratory Pressure.

We offer the following PEP therapy options:

• PARI PEP Systems: Enable an effective combination of PEP and inhalation therapy. The resistance in the PEP Systems creates a back pressure when breathing out, preventing the airways from collapsing. This enables more medication to reach the peripheral airways during the breathing in phase. Clearance by coughing is easier, and more air from the lungs can be exhaled.

• PARI O-PEP: Respiratory therapy device for effective mucus clearance, used in addition to nebulisation; the vibration generated when exhaling into the O-PEP helps to dislodge stubborn mucus from the bronchial walls which can then be expectorated more easily.

PEP

SYST

EMS

46

Lower airways

PARI PEP Systems

• Mobilises secretions and makes clearance by coughing easier

• Stabilisation of the airways with individually adjustable expiratory resistance: counteracts bronchial collapse

• Pressure gauge for adjusting expiratory resistance and monitoring during PEP treatment (PARI PEP System II)

• Can also be used without a nebuliser in physiotherapy

Time-saving combination of physiotherapy and inhalation therapy


Pressure gauge 0 – 100 mbar, with pressure hose + 3 tubing adapters

018B1600 –

PARI PEP tubing adapter 3 units made from silicone, including1 adapter for the pressure gauge

041G4580 –

PARI PEP S Systemfor all PARI nebulisers except PARI LC SPRINT BABY

PARI PEP System Icompatible with PARI LC PLUS and PARI LL Nebulisers without pressure gauge

Item No. 018G4000

PARI PEP S SystemPARI PEP System I

Item No. 018G6101

47

PARI O-PEP

• Oval mouthpiece for comfortable treatment sessions

• Alleviates unproductive coughing and shortness of breath

• Including small bag for hygienic storage and transport

• Dishwasher-safe and sterilisable up to 134 ° C

Efficiently loosens bronchial mucus and strengthens the airways

PARI O-PEP

Item No. 018G5000

The long-term respiratory therapy device allowing effective, convenient, repetitive mobilization of bronchial mucous for patients of all age groups suffering from CF, COPD, bronchiectasis or (severe) Asthma.

With its oval mouthpiece, the PARI O-PEP offers a comfortable therapy during multiple therapy sessions per day.

PEP

SYST

EMS

49

The same also holds true for the treatment of airways: No therapy without well-founded diagnosis and long-term therapy monitoring. We at PARI want to create an even closer link between diagnosis and therapy by making new technologies and holistic solutions available. We offer products that are specifically designed to meet the requirements of the medical community as well as the needs of patients using the devices at home. The combination of medical applications and patient monitoring is a chance for a more comprehensive lung function diagnosis and therapy observation.

A good example of this is the SpiroSense. SpiroSense is an innovative spirometry system. It comprises a professional PC spirometer for use by healthcare professionals and a mobile patient spirometer for optional monitoring of lung function at home. Combining the two spirometers, measurements generated by healthcare professionals can be supplemented by measurements generated by the patient at home.

The home monitoring spirometer stores an entire flow-volume curve of each measurement. A traffic light feedback enables the patient to objectify his self-assessment. Via USB, the data stored in the home monitoring spirometer can be easily transferred to the healthcare professional, during the next visit to the doctor. SpiroSense will not only help the doctor with his diagnosis but also with setting up and optimising treatment plans.

Diagnostics

DIA

GN

OST

ICS

50

SpiroSense®Pro

• High measurement accuracy 2 enabled by new heated wire sensor technology

• Time and cost savings due to ease of handling and automatic calibration

• Software animation to promote and support correct respiration cycle

• Home monitoring option when using a mySpiroSense patient spirometer

• New international GLI 3 reference values and ATS 5/ERS 6-conform measurements

The easy to use spirometer for healthcare professionals

The SpiroSensePro combines intuitive application with many convenience functions for a simple, reliable lung function measure-ment. Real-time display of flow-volume curves and a child-friendly 1 software animation depict the entire respiratory cycle. This enables fast results and ensures high compliance.

1 Dormeyer, C. et al 2014, Allergologie, 37(4), 1612 Friedrich P., internal report by the Hochschule für angewandte Wissenschaften Kempten, Fakultät Elektrotechnik [Kempten University of Applied Sciences, Electronics and electrical engineering faculty ], 20143 GLI = Global Lung Function Initiative4 Quanjer PH et al. Eur Respir J. 2012; 40:1324-13435 ATS = American Thoracic Society6 ERS = European Respiratory Society

PC Spirometer SpiroSensePro

Item No. 120G1200

Technical data:

Values de-termined with PC spirometer Spiro SensePro

FVC, FEF25 (MEF75), FEF50 (MEF50), FEF75 (MEF25), FEF25-75, FET, FEV0.5, FEV0.5/FVC, FEV0.75, FEV0.75/FVC, FEV1, FEV1/FVC, FEV3, FEV6, FIV1, FIVC, FIV1/FIVC, PEF, PIF, FV curve

Reference values database

In accordance with the reference values of GLI 3 for children aged 3 years and older 4

Size/weight

160 × 83 × 45 mm/ < 200 g

Measurement Range/ Measurement Accuracy:

Flow rate10 – 840 l/min/ 5%/10l/min

Volume0.1 – 9.9 l/

±3 %/0,05 l


51

Patient Spirometer mySpiroSense

Item No. 120G1100

Measurement Range/ Measurement Accuracy:

Flow rate10 – 840 l/min/

5%/10l/min

Volume0.1 – 9.9 l/

±3 %/0,05 l

mySpiroSense®

The mobile spirometer for the patient

• Same measurement accuracy and technology as SpiroSensePro

• Electronic diary including complete flow-volume curves

• More values enabling more meaningful conclusions: FEV 1, FVC, PEF, FEV 1/FVC, FEV 0.5, FEV 0.75, FEF 75, FEF 50, FEF 25-75

• A traffic light feedback enables the patient to objectify his self-assessment

• Small and mobile due to battery operation

The battery-powered mySpiroSense patient spirometer with intuitive operation enables patients to measure their lung function at home. The device assists patients executing objective self-assessments and offers doctors a closely integrated, reliable monitoring option. The chronological data series of measurement values and the associated flow-volume curves are clearly displayed to facilitate detailed analysis.

Technical data:

Values deter-mined with patientspirometer mySpiro Sense

FEV1, FVC, PEF, FEV1/FVC, FEV0.5, FEV0.75, FEF50 (MEF50), FEF75 (MEF25), FEF25-75, FV curve

Size/weight160 × 83 × 45 mm/ < 200 g


DIA

GN

OST

ICS

52

The PARI PEAK FLOW METER is used to measure expiratory flow strength. With regular peak flow measurements, even small changes in bronchial obstruction can be detected. The timely administration of medicinal substances can bring bronchial obstructions under control, e.g. preventing a serious asthma attack. The peak flow log can be used for assessing whether the medications prescribed by the doctor are having the desired effect.

• Easy, simple therapy monitoring for doctor and patient

• With convenient traffic light function (red/amber/green) for individual monitoring of the patient's general health

• Including 4-week log

PARI PEAK FLOW METERFor optimum self-monitoring

PARI PEAK FLOW METER Kids Measurement range 50 – 800 l/minWith narrow mouthpiece

Item No. 031G0001

PARI PEAK FLOW METER Measurement range 50 – 800 l/min for adults

Item No. 031G0000


53

Clinic ProductsInhalation devices and nebulisers are typically used by multiple patients in the hospital and the doctor‘s surgery. This is why stricter hygiene regulations apply in these environments compared to using the devices at home. Hygienic prepa-ration for re-use according to validated processes is essential after every use. The nebuliser must be cleaned, disinfected and sterilised.

To satisfy these requirements, our nebulisers and even the VORTEX spacer are disinfectable, sterilisible and autoclavable. Connection tubes must be cleaned mechanically and disinfected before they are used by another patient, or they must be replaced. A further advantage of our hospital portfolio are the pack sizes. These have been adjusted for the increased need in a hospital or doctor‘s surgery.

You will find more information on the following pages.

CLI

NIC

PR

OD

UC

TS

54

Clinic Products

PARI LC SPRINT Nebuliser (blue nozzle attachment)with universal mouthpieceand long connection tubing

Technical data:

Can be used with:

PARI CENTRAL AIR and O2

Item No. 023G5800

PARI CENTRAL

• In two variations: for connection to compressed air or to oxygen

• No time-consuming adjustments, simply connect it up

• Fixed operating flow – ideal for PARI nebulisers

• Maintenance-free


The aerosol characteristics of PARI nebulisers in combination with the CENTRAL, a compressed air source of 1.6 bar:

PARI LC SPRINT Junior*


MMD: 2.9 μm


76 %

PARI LC SPRINT STAR**


MMD: 2.2 μm


89 %

PARI LC SPRINT**


MMD: 3.5 μm


67 %

Measurement with Malvern Mastersizer Xat 23 °C and 50 % relative humidity.Nebulised medium: 0.9 % NaCl (5 ml).* Inspiratory flow 12 l/min.** Inspiratory flow 20 l/min.

Product variants Item No. Page

PARI CENTRAL AIRWall outlet fitting for compressed air compliant with DIN13260-2 incl. PARI CENTRAL connection tubing (f/f)** +adapter, specifically for the compressed air system in a hospital

058G1100 –

PARI CENTRAL O2

Wall outlet fitting for compressed air compliant with DIN13260-2 incl. PARI CENTRAL connection tubing (f/f)** +adapter, specifically for the compressed air system in a hospital

058G1200 –

CENTRAL AIR (compliant with SS 87524 30) 058G1110 –

CENTRAL O2 (compliant with SS 87524 30) 058G1210 –

CENTRAL AIR (compliant with NF S 90-116) 058G1130 –

CENTRAL O2 (compliant with NF S 90-116) 058G1230 –

Wall outlet fitting for the central gas supply in the hospital

* female/male, ** female/female

55

• Powerful continuous nebuliser (blue nozzle attachment) for efficient deposition in the central region of the lungs (for ages 4 and older)

• A small number of single parts means that it can be ready for use very quickly

• Easy assembly

• Convenient medication fill level display

PARI LC SPRINT Nebuliser(blue nozzle attachment)with universal mouthpieceand long connection tubing

Technical data:

Can be used with:

PARI CENTRAL AIR and O2

Item No. 023G5800



MMD: 3.5 μm

Mass fractions > 5 μm:

67 %

Measurement taken with Malvern Spraytec) at 23 °C and 50% relative humidity.Nebulised medium: 0.9% NaCl (6 ml).Inspiratory flow 20 l/min.


Connection tubing, long (f/f)** 041G4550 –

PARI adult mask softwith mask stabiliser – hospital pack (5 units each)

041G0747 57

PARI mask stabiliser(for adult mask soft, pack of 5)

041G0749 57

PARI child mask softwith mask stabiliser – hospital pack (5 units each)

041G0746 57

PARI mask stabiliser(for PARI child mask soft, pack of 5)

041G0748 57

PARI CENTRAL Clip(pack of 5)

058G2001 –

PARI LC SPRINT® CENTRALNebuliser specifically for use with the PARI CENTRAL in hospitals

CLI

NIC

PR

OD

UC

TS

56


VORTEX mouthpiece with valve (10 units) 051G5101 39

PARI BABY mask size 0with BABY bend for premature babies

041G0700 29

PARI BABY mask size 1with BABY bend for approx. 0–1 year

041G0701 29

PARI BABY mask size 2with BABY bend for approx. 1–3 years

041G0702 29

PARI BABY mask size 3with BABY bend for approx. 3 years and older

041G0703 29

PARI SMARTMASKfor adults, including 45-degree bend

041G0730 30

PARI SMARTMASK Kidsfor age approx. 2 years and older

078G5000 30

VORTEX®

VORTEX Hospital pack 10 units

Item No. 051G5100

The antistatic holding chamber – small, solid and effective

The antistatic holding chamber VORTEX helps to minimise these disadvan-tages. The MDI is triggered into the VORTEX. The patient can then inhale the medication from the holding chamber in their own time. The need to ‘press and inhale simultaneously‘ is minimised and more medication reaches the lung, making the therapy as a whole safer and more effective.

Medication sprays or MDIs are often used to treat respiratory diseases such as asthma or COPD. The principle of a MDI is that you ‘press and inhale simultaneously’. For some patients like children and the elderly, getting this coordination right can be difficult. Poor coordination results in less medication reaching the lung and being deposited in the mouth and throat instead. The positive effect of the therapy can be reduced and undesirable side effects can result.

• Antistatic metal chamber helps to ensure reliable dosage

• Universal adapter for all popular metered dose inhalers

• Visual control for monitoring spray release

• Protective cap for extra hygiene protection

• Cyclone twist principle supports the transport of small aerosol droplets

• Confident hygiene: Can be disinfected and sterilised at 134º C

57

Nebulisers and Accessories

Item No. 023G1080PARI LC SPRINT® Tracheomedication nebuliser with valve system (blue nozzle attachment), LC Tracheo Adapter and long connection tubing (f/f)**

** female/female

Item No. 023G6010

more on page 34/35

Item No. 023G6011

more on page 34/35

Item No. 023G6012

more on page 34/35

PARI LC SPRINT® – hospital pack (10 units)medication nebuliser with valve system (blue nozzle attachment) and universal mouthpiece, without connection tubing

PARI LC SPRINT® Junior hospital pack (5 units)medication nebuliser with valve system for children(yellow nozzle attachment) and universal mouthpiece, without connection tubing

PARI LC SPRINT® STAR – hospital pack (5 units)fine droplet nebuliser with PIF Control and valve system (red nozzle attachment), universal mouthpiece, without connection tubing

Item No. 041G0747

Item No. 041G0749

Item No. 041G0746

Item No. 041G0748

PARI Adult mask soft with mask stabiliser – hospital packPARI Adult mask soft and PARI Mask stabiliser, pack of 5 each

PARI Mask stabiliser(for PARI Adult mask soft) stabiliser forsterilisation in the autoclave, pack of 5

PARI Child mask soft with mask stabiliser – hospital packPARI Child mask soft and PARI Mask stabiliser, pack of 5 each

PARI Mask stabiliser(for PARI Child mask soft) stabiliser forsterilisation in the autoclave, pack of 5

CLI

NIC

PR

OD

UC

TS

58

PARI Filter/Valve Set

• Prevents inhaled medications from being exhaled into the ambient air

• Protects individuals who are indirectly concerned with the inhalation, e.g. family members and nursing staff, from breathing in the medication aerosol

• This is particularly important for inhaled substances such as antibiotics, steroids, antimycotics

• The integrated valve system ensures efficient inhalation treatment

• The filter pad is very easy to replace

For pure air

PARI Filter/Valve Set for all nebulisers in the PARI LC SPRINT Family, PARI LC PLUS Family and eFlow®rapid nebulisers

Item No. 041G0500


PARI Filter Pad, Pack of 30 041B0522 –



CLI

NIC

PR

OD

UC

TS

60

PARI, your reliable partner. Worldwide!

PARI MEDICAL HOLDING GmbH

Moosstraße 382319 StarnbergTel.: +49 8151 279-0Fax: +49 8151 [email protected]

PARI GmbH

Spezialisten für effektive InhalationMoosstraße 382319 StarnbergTel.: +49 8151 279 0Fax: +49 8151 279 101E-Mail: [email protected]

USA

PARI Respiratory Equipment, Inc.

2412 PARI WayMidlothian, VA 23112, USAToll Free (U.S.A. only)Phone: 1 800 FAST NEB (327.8632)Fax: 1 800 727 4112Canada and InternationalPhone: 1 804 253 PARI (7274)Fax: 1 804 253 0260E-Mail: [email protected]

PARI International

PARI Headquarter in GERMANY

61

You can find the addresses of our service partners and distributors on

http://www.pari.com/partners

PARI Pharma GmbH

Lochhamer Schlag 2182166 GräfelfingTel: +49 89 742 846-0Fax: +49 89 742 846 [email protected]/pharma

France

PARI PulmoMed S.A.R.L.

11 avenue de l‘Île Saint-MartinZ.A. du Petit Nanterre92737 Nanterre CedexTel.: +33 1 56 83 85 00Fax: +33 1 56 83 85 [email protected]

United Kingdom

PARI MEDICAL Ltd.

The Old Sorting OfficeRosemount AvenueWest ByfleetSurrey KT14 6LB, UKTel: +44 (0)1932 341122Fax: +44 (0)1932 [email protected]

Russia

PARI synergy in medicine LLc.

Novocheremuschkinskaya str. 49Office 17-18117418 MoscowTel: +7 495 981 88 60Fax: +7 495 981 88 [email protected]

PARI Headquarter in GERMANY

62

PARI Publication List

The stated objective of Research and Development at PARI and PARI Pharma is to develop optimal complete solutions, i.e., medications and inhalation systems for defined clinical pictures and patient groups. In all our development efforts, our primary focus is always to serve the needs of patients, for whom inhalation treatment should be as simple, comfortable and efficient as possible. The benefits for patients may take the form of short inhalation times combined with economical use of medications, or simpler, more convenient application due to reduced frequency, for example. Many scientific publications attest to our unceasing efforts and endeavours to develop efficient systems:

Adeboyeku D. et al. J Cyst Fibros. 2006; 5(4):261 Al-Amoud A. I. et al. 2005; Br J Clin Pharmacol. 59(5):542 Albasarah Y. Y. et al. 2010; J Pharm Pharmacol. 62(7):821 Alothman G. A. Chest. 2005; 127(2):522Amin R. et al. 2010 Thorax 65: 379 Arzhavitina H. & Steckel H. 2010; Int J Pharm. 384(1-2):128 Basu K. et al. Ann Allergy Asthma Immunol. 2009; 103(5):436 Bauer A. et al. 2009; Resp. Care. 2007:1 Bauer A. et al. 2009; Resp. Care. 54(10):1342Bauer A. et al. 2009; Resp. Care. 54(11):1488 Berg E.B. & Picard R. J. 2009; Respir Care. 54(12):1671Bergsson G. et al. 2009 J Immunol. 183(1):543 Berlinski A. & Hayden J. B. Pediatr Pulmonol. 2010; 45(suppl 33):369 Berlinski A. & Waldrep J. C. 2006; J Aerosol Med. 19(4):484 Berlinski A. Respir Care. 2014 Feb;59(2):216-22Bilton D. at al. ERS conf. 2011, oral presentation 1925 Bilton D. et al. Am J Respir Crit Care Med. 2010; 181:A3191 Bilton D. et al. ECFC 2014 oral presentation WS7.3Bilton D. et al. NACF 2014 P284Boerner G. et al. ECFC 2014 P285Bondesson E. et al. 2007; Br J Clin Pharmacol. 63(6):722 Boogaard R. et al. Thorax . 2008; 63(2):141 Bosco A. P. et al. 2004; CHEST. 6(4_MeetingAbstracts):816S Bosco A. P. et al. 2005; J Aerosol Med. 18(4):427 Bourdet D. et al. ERS 2014 P1892Brand P. et al. 2003; Eur Respir J. 22(2):263 Bruinenberg D. et al. Am J Respir Crit Care Med. 2010; 181:A3192 Byrne N. M. et al. Arch Dis Child. 2003; 88(8):715 Clavel A. et al. 2007; J Cyst Fibros. 6(2):137 Coates A. L. et al. 2007; J Aerosol Med. 20(3):320 Coates A. L. et al. 2009; NACF poster Coates A. L. et al. Pediatr Pulmonol. 2008; 43(s31):367 Colaneri M. et al. Ital J Pediatr. 2014 Feb 13;40(1):18.Colombier L. et al. 2004; Rev Mal Respir Abstract 70 Corcoran T. E. et al. 2006; Am J Transplant. 6(11):2765 Costantini D. et al. ERS conf. 2003 Dahlström K. et al. 2003; Ann Allergy Asthma Immunol.2003; 90(2):226 Davidson H. et al. 2006; Am J Respir Cell Mol Biol. 2006; 35(1):72 Davies J. et al. 2010; Am J Respir Crit Care Med. 181:A2193 de Boer A. H. et al. 2003; Int J Pharm. 268(1-2):59 Dellon E. P. et al. 2008; Pediatr Pulmonol. 43:1100 Dennis J. H. et al. 2002; J Cyst Fibros. 1(suppl 2):209 Dentice R. L. et al. 2012; J Physiother. 58(1):33 Deterding R. et al. Pediatr Pulmonol. 2005; 39(4):339 Devadason S. G. et al. ATS conf. 2003 oral pres.

Devadason S. G. et al. DDL conf. 2012 oral pres.Dimakou K. et al. ERS 2014 P244Donaldson S. H. et al. 2006; N Engl J Med. 354(3):241 Durairaj L. et al. J Cyst Fibros. 2007; 6(1):31Durairaj L. et al. J. Respir Res. 2006; 7(1):27 Durairaj L. et al. Respir Res. 2004; 5(1):13 Elhissi A. et al. 2013; Int J Pharm. [epub Jan 5] Elkins M. R. et al. 2006 N Engl J Med 354:229 Evans R. et al. DDL Edinburgh. 2005; XVI(dec 7–9):121 Fischer R. et al. 2006; ERS conf.; P2932 Fischer R. et al. J Cyst Fibr. 2007; 6(suppl 1):S41 Geller D. E. et al. 2003; Chest. 123(1) Geller D. E. et al. Chest. 2002; 122(1):219 Geppe N. et al. ERS conf. 2008: 3985 Geppe N. et al. ERS conf. 2009: 4029 Gerber A. et a. ECFC 2014 P300Gorinova Y. et al. ERS 2014 P243Griese M. et al. 2004; Am J Respir Crit Care Med. 2004;169(7):822 Griese M. et al. J Aerosol Med Pulm Drug Deliv. 2014;27(3):185-92.Griese M. et al. Pediatr Pulmonol. 2009; 44(s32):300 Grimbert D. et al. 2003; J Aerosol Med. 16(2):121 Grzelewska-Rzymowska I. et al. Respir Med. 2003;97(suppl b):21–26 Hallstrand T. S. et al. 2004; Eur Respir J. 24(3):367 Hallstrand T. S. et al. Eur Respir J. 2004; 24(3):367 Hanga D. et al. 2012; 83rd Ann. Meeting of the German Soc. of Otorhinolaryng., Head and Neck Surgery Hardaker L. E. et al. 2006; J Cyst Fibros. 5(suppl. 1):S41 Häußermann S. et a. 2005; Eur Respir J. 26(suppl 49):s729s Hennig S. et al. J Cyst Fibros. 2014 Jul;13(4):428-34.Hickey A. J. et al. 2006; J Aerosol Med. 19(1):54 Hodson M. E. et al. Eur Respir J. 2002; 20(3):658 Hofmann T. et al. 2012; Curr Pharm Des. 18(5):683 Hubert D. et al. J Cyst Fibros. 2007; 6(suppl 1):12 Hubert D. et al. J Cyst Fibros. 2009; 5(5):332 Hullard-Pulstinger A. et al. Onkologie 2011;34:254 Jaafar-Maalej et al. 2010;J Liposome Res. 20(3):228-43Junge Hülsing B. P. Abstracts HNO Inform. 2004 Katsumi N. et al. ORL Tokyo. 2008; 51(1):15 Katz S. L. et al. 2006; . Pediatr Pulmonol. 2006; 41(7):666 Kesser K. C. & Geller D. E. 2010; J Cyst Fibros. 9(suppl 1):61Kofman C. D. et al. 2010; J Cyst Fibros. 9(suppl 1):62 Köhler E. et al. 2004; J Aerosol Med. 17(2):116 Köhler E. et al. 2005; J Aerosol Med. 18(4):386 Konstan M. W. et al. J Cyst Fibros. 2011; 10(1):54Kwok P. et al. 2010; J Aerosol Med Pulm Drug Deliv. 2010; 23(3):1 Laube B. L. et al. 2011; BMC Pulm Med. 11:45

63

Lenney W. et al. J Cyst Fibros. 2011; 10(1):9 Leung K. et al. 2004; Chest. 126(5):1619Leung K. et al. 2007; J Gene Med. 9(1):10 Lin H. S. et al. 2012; Respir Care. 57(11):1894 Lindstrom M. et al. 2004; Respir Med. 98(1):9 Lipworth B. J. et al. Br J Clin Pharmacol. 2005; 29(1):5 Maillet A. et al. 2007; Pharm Res. epub Mainz J. G. et al. 2012; J Cyst Fibros. 11(2):158 Mainz J. G. et al. Auris Nasus Larynx. 2010; 1:1 Mainz J. G. et al. ECFC conf. 2011 P83 Mainz J. G. et al. J Cyst Fibros. 2009; 8(suppl 2):69 Mainz J. G. et al. J Cyst Fibros. 2010; 9(suppl 1):23 Mainz J.G. et al. Drug Des Devel Ther. 2014 Feb 10;8:209-17.Mainz J.G. et al. J Cyst Fibros. 2014 Jul;13(4):461-70.Majoral C. et al. 2006; Respir Med. epub Mansour M. et al. Respir Care. 2012 Jun 15.[Epub]Mazurek H. et al. Pediatr Pulmonol. 2014 Nov;49(11):1076-89.McKenzie J. E. et al. 2004; Ann Pharmacother. 38(6):967 McLachlan G. et al. 2007; Mol Ther. 5(2):348 Melani A. S. et al. 2006; Rassegna di Patol. dell‘App. Resp. 21:61Milani G. K. et al. J Pediatr (Rio J) 004; 80(2):106 Militz S. et al. J Cyst Fibros. 2008; 7(2):S67 Moeller W. et al. RDD conf. 2007 Moeller W. et al. RDD conf. 2008Montgomery A.B. et al. Antimicrob Agents Chemother. 2014 Jul;58(7):3714-9.Montgomery A.B. et al. J Aerosol Med Pulm Drug Deliv. 2014 Dec;27(6):441-8.Moss R. B. Chest. 2002; 121(1):55 Moss R. B. et al. Chest. 2004; 125(2):509 Nadithe V. et al. 2003; J Pharm Sci. 92(5):1066 Naruto R. et al. ORL Tokyo. 2008; 51(1):11 Nasr M. et al. Int J Pharm. 2014 Jan 30; 461(1-2):242-50.Navratil T. et al. 2010; ECFC conf.Nerbrink O. L. et al. 2003; Aerosol Sci Technol. 37(3):282 Newman S. P. et al. 2005; J Aerosol Med. 18(2):249O‘Connell O. J. et al. 2011; Respir Care. 56(6):771 Olivier K. N. et al. NACF 2014 P293Omri A. et al. ECFC 2014 oral presentation WS2.1Perkins W. et al. Pediatr Pulmonol. 2007(suppl 30):356Perkins W. R. 2010; J Aerosol Med Pulm Drug Deliv. 23(2):113 Peters M. M. et al. Thorax. 2006; 61(7):559 Petrigni G. et al. ERS conf. 2004 Poli G. & Acerbi D. Respir Med. 2003; 97(Suppl B):5–9Poli G. et al. 2006; J Cyst Fibr. 5 (suppl1):S43 Poli G. et al. 2007; Pediatr Drugs 9 Suppl. 1: 3 Potter R. et al. 2010; J Cyst Fibros. 9(suppl 1):24 Pullamsetti S. et al. 2005; Respir Res. 2005; 6:128 Ratjen F. 2006; Curr Opin Pulm Med. 2006; 12(6):428 Rau J. L. et al. 2004; Respir Care. 49(2):174 Reeves E. P. et al. 2011; Am J Respir Crit Care Med.183(11):1517 Reychler G. et al. 2009; ECFC conf.Rohatagi S. et al. 2004; Am J Ther. 11(2):103 Rosenfeld M. et al. 2011; Pediatr Pulmonol. 46(7):666Rosenfeld M. et al. 2012; JAMA. 307(21):2269 Roth A. P. et al. 2003; J Aerosol Med. 16(3):325

Rottier B. L. et al. 2009; J Aerosol Med Pulm Drug Deliv. 22(2):1 Rudolph C. et al. 2004; Pharm Res. 21(9):1662Sands D. et al. J Cyst Fibros. 2014 Dec;13(6):653-60.Scherer T. et al. 2011; J Pharm Sci. 100(1):98 Serisier D. J. et al. ERS conf. 2011, oral pres. 1928 Serisier D.J. et al. Thorax. 2013 Sep;68(9):812-7.Shrewsbury S. B. et al. 2009; Int J Pharm. 365(1-2):12 Sood N. et al. Am J Respir Crit Care Med. 2003; 167(2):158 Tavakkol A. et al. 2007; NACF conf. Tazawa R. et al. 2005; Am J Respir Crit Care Med.171(10):1142 Tazawa R. et al. Am J Respir Crit Care Med. 2005; 171(10):1142 Tazawa R. et al. Respirology. 2006; 11(suppl):61–4 Terzano C. et al.2007; Eur Rev Med Pharmacol Sci. 11(4):225 Tiemersma S. et al. J Aerosol Med Pulm Drug Deliv. 2013 Oct;26(5):280-6.Tiffin N. et al. ATS conf. 2010: P1494 Topini T. C. M. et al. 2008; J Cys Fibr. 7(suppl 2):S65Twiss J. et al. Int J Pharm. 2005; 295(1–2):113 Uluer A. Z. et al. 2012; J Cyst Fibr. epub Oct 6 Vaghi A. et al. 2005; Pulm Pharmacol Ther. 2005; 18(2):151 Van Erp C. et al. 2007; ). Pediatr Pulmonol. 2007(suppl 30):342 Vecellio L. et al. 2009; Int J Pharm. 371(1-2):99 Vecellio L. et al. 2009; J Cyst Fibros. 8 (Suppl 2):S66 Vecellio L. et al. 2011 J Cyst Fibros. 10(2):86-92 Walz-Jung H. et al. ERS 2014 P3570Wang Z. et al. 2003; J Pharm Pharm Sci. 6(1):95 Weers J. et al. ATS conf. 2005: L4 Wenzel S. et al. Lancet. 2007; 370:1422 Westerman E. M. et al. 2008; ECFC conf. Westerman E. M. et al. 2008; J Aerosol Med Pulm Drug Deliv. 21(3):269 Wong-Beringer A. et al. 2005; Chest 128;3711 Zeiger R. S. et al. N Engl J Med 2011;365:1990 Zhou Y. et al. 2005; J Aerosol Med. 18(3):283

041D

0282

-G-0

9-20

17

PARI GmbH Moosstraße 382319 StarnbergGERMANYEmail: [email protected]. +49 (0) 8151 279 0Fax +49 (0) 8151 279 101www.pari.com

We’re here to help!

PARI‘s Export Service Coordinators in Starnberg, Germany, offer an

expert service and are dedicated to assisting you personally with any

questions regarding:

• Use and handling of PARI inhalation devices

• Cleaning and servicing

• Accessories and spare parts

• Product availability and lead-times

• Order processing and logistics

If you need information about a repair or service for a PARI device,

please visit www.pari.com/partners to find a distributor and/or service partner

in your country.

We look forward to hearing from you.

Simply give us a call or send an email to [email protected] for a prompt response.

PARI SERVICE CENTER

+49 (0) 8151 279 220

2017 2018 · PARI PRODUCT OVERVIEW 2017 / 2018 BREATHE FREELY. WITH PARI. oduct overview 2017 /...

Documents

Transcript of 2017 2018 · PARI PRODUCT OVERVIEW 2017 / 2018 BREATHE FREELY. WITH PARI. oduct overview 2017 /...